Myopic Choroidal Neovascularisation
8
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
The Treatment Burden of Myopic Choroidal Neovascularization
Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients
VISUPRIME® Eye Drops
OCTA Changes in Choroidal Neovascularization in High Myopia
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
Effect of Corona Virus on Intravitreal Injections
Real Life Study in Myopic Neovascularization
CM082 in Patients With Myopic Choroidal Neovascularization (CNV)